BR102013020313A8 - derivados bifeniloxi-alquil-aminas e ariloxi-alquil-aminas, composição farmacêutica, uso da composição farmacêutica no tratamento ou prevenção ou inibição de doenças inflamatórias pulmonares crônicas e método de tratamento ou prevenção destas doenças - Google Patents

derivados bifeniloxi-alquil-aminas e ariloxi-alquil-aminas, composição farmacêutica, uso da composição farmacêutica no tratamento ou prevenção ou inibição de doenças inflamatórias pulmonares crônicas e método de tratamento ou prevenção destas doenças

Info

Publication number
BR102013020313A8
BR102013020313A8 BR102013020313A BR102013020313A BR102013020313A8 BR 102013020313 A8 BR102013020313 A8 BR 102013020313A8 BR 102013020313 A BR102013020313 A BR 102013020313A BR 102013020313 A BR102013020313 A BR 102013020313A BR 102013020313 A8 BR102013020313 A8 BR 102013020313A8
Authority
BR
Brazil
Prior art keywords
alkyl
prevention
treatment
pharmaceutical composition
diseases
Prior art date
Application number
BR102013020313A
Other languages
English (en)
Other versions
BR102013020313A2 (pt
BR102013020313B1 (pt
Inventor
Teixeira Da Silva Emerson
Carlos Santos Da Costa Jorge
Fraguas Serra Magda
Aurélio Martins Marco
Vinicius Nora De Souza Marcus
Xavier Faria Robson
Original Assignee
Fundacao Oswaldo Cruz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao Oswaldo Cruz filed Critical Fundacao Oswaldo Cruz
Priority to BR102013020313-0A priority Critical patent/BR102013020313B1/pt
Priority to EP14834562.2A priority patent/EP3031794B1/en
Priority to PCT/BR2014/000266 priority patent/WO2015017906A1/pt
Priority to CN201810769782.3A priority patent/CN108912005B/zh
Priority to US14/911,138 priority patent/US20160214926A1/en
Priority to CA2920315A priority patent/CA2920315C/en
Priority to JP2016532166A priority patent/JP6602297B2/ja
Priority to CN201480049930.4A priority patent/CN105517991B/zh
Priority to MX2016001747A priority patent/MX370251B/es
Priority to ES14834562T priority patent/ES2717125T3/es
Publication of BR102013020313A2 publication Critical patent/BR102013020313A2/pt
Publication of BR102013020313A8 publication Critical patent/BR102013020313A8/pt
Publication of BR102013020313B1 publication Critical patent/BR102013020313B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

derivados bifeniloxi-alquil-aminas e ariloxi-alquil-aminas, composição farmacêutica, uso da composição farmacêutica no tratamento ou prevenção ou inibição de doenças inflamatórias pulmonares crônicas e método de tratamento ou prevenção destas doenças. a presente invenção refere-se a derivados bifeniloxi-alquil-aminas e ariloxi-alquil-aminas, estruturalmente análogos à mexiletina, com importantes atividades biológicas e desprovidos dos efeitos colaterais não desejáveis presentes no protótipo, bem como em outros fármacos da mesma classe terapêutica do protótipo. os derivados da presente invenção possuem as fórmulas ii e iii e são usados no tratamento ou prevenção ou inibição de doenças inflamatórias pulmonares, a exemplo da asma e doença pulmonar obstrutiva crônica (dpoc).
BR102013020313-0A 2013-08-09 2013-08-09 derivados bifeniloxi-alquil-aminas e ariloxi-alquil-aminas, e, composição farmacêutica BR102013020313B1 (pt)

Priority Applications (10)

Application Number Priority Date Filing Date Title
BR102013020313-0A BR102013020313B1 (pt) 2013-08-09 2013-08-09 derivados bifeniloxi-alquil-aminas e ariloxi-alquil-aminas, e, composição farmacêutica
EP14834562.2A EP3031794B1 (en) 2013-08-09 2014-08-06 Diphenyloxyalkylamine derivatives and aryloxyalkylamine derivatives, pharmaceutical composition, use of said pharmaceutical composition for treating, preventing or inhibiting chronic pulmonary inflammatory diseases and method for treating or preventing such diseases
PCT/BR2014/000266 WO2015017906A1 (pt) 2013-08-09 2014-08-06 Derivados bifeniloxi-alquil-aminas e ariloxi-alquil-aminas, composição farmacêutica, uso da composição farmacêutica no tratamento ou prevenção ou inibição de doenças inflamatórias pulmonares crónicas e método de tratamento ou prevenção destas doenças
CN201810769782.3A CN108912005B (zh) 2013-08-09 2014-08-06 二苯氧基烷基胺衍生物及其药物组合物
US14/911,138 US20160214926A1 (en) 2013-08-09 2014-08-06 Diphenyloxyalkylamine derivatives and aryloxyalkylamine derivatives, pharmaceutical composition, use of said pharmaceutical composition for treating, preventing or inhibiting chronic pulmonary inflammatory diseases and method for treating or preventing such diseases
CA2920315A CA2920315C (en) 2013-08-09 2014-08-06 Diphenyloxyalkylamine derivatives and aryloxyalkylamine derivatives, pharmaceutical composition, use of said pharmaceutical composition for treating, preventing or inhibiting chronic pulmonary inflammatory diseases and method for treating or preventing such diseases
JP2016532166A JP6602297B2 (ja) 2013-08-09 2014-08-06 ジフェニルオキシアルキルアミン誘導体およびアリールオキシアルキルアミン誘導体、薬学的組成物、慢性肺炎症性疾患を治療、予防、または阻止するための前記薬学的組成物の使用、ならびにそのような疾患を治療または予防するための方法
CN201480049930.4A CN105517991B (zh) 2013-08-09 2014-08-06 一种芳氧基烷基胺衍生物、药物组合物及其制药用途
MX2016001747A MX370251B (es) 2013-08-09 2014-08-06 Derivados de difeniloxialquilamina y derivados de ariloxialquilamina, composicion farmaceutica, uso de dicha composicion farmaceutica para tratar, prevenir o inhibir enfermedades inflamatorias pulmonares cronicas y metodo para tratar o prevenir dichas enfermedades.
ES14834562T ES2717125T3 (es) 2013-08-09 2014-08-06 Derivados de difeniloxialquilamina y derivados de ariloxialquilamina, composición farmacéutica, uso de dicha composición farmacéutica para tratar, prevenir o inhibir enfermedades inflamatorias pulmonares crónicas y método para tratar o prevenir tales enfermedades

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102013020313-0A BR102013020313B1 (pt) 2013-08-09 2013-08-09 derivados bifeniloxi-alquil-aminas e ariloxi-alquil-aminas, e, composição farmacêutica

Publications (3)

Publication Number Publication Date
BR102013020313A2 BR102013020313A2 (pt) 2015-10-06
BR102013020313A8 true BR102013020313A8 (pt) 2021-02-23
BR102013020313B1 BR102013020313B1 (pt) 2021-07-06

Family

ID=52460438

Family Applications (1)

Application Number Title Priority Date Filing Date
BR102013020313-0A BR102013020313B1 (pt) 2013-08-09 2013-08-09 derivados bifeniloxi-alquil-aminas e ariloxi-alquil-aminas, e, composição farmacêutica

Country Status (9)

Country Link
US (1) US20160214926A1 (pt)
EP (1) EP3031794B1 (pt)
JP (1) JP6602297B2 (pt)
CN (2) CN105517991B (pt)
BR (1) BR102013020313B1 (pt)
CA (1) CA2920315C (pt)
ES (1) ES2717125T3 (pt)
MX (1) MX370251B (pt)
WO (1) WO2015017906A1 (pt)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031244A (en) 1966-09-16 1977-06-21 Boehringer Ingelheim Gmbh Pharmaceutical compositions containing a 1-(2,6-dimethyl-phenoxy)-2-amino-alkane and method of use
DE1643240A1 (de) 1966-09-16 1971-06-24 Boehringer Sohn Ingelheim Verfahren zur Herstellung neuer racemischer oder optisch aktiver 1-Phenoxy-2-aminoalkane
CN1246845A (zh) * 1997-02-04 2000-03-08 纳幕尔杜邦公司 杀菌的羧酰胺
AU5464901A (en) * 2000-03-01 2001-09-12 Nihon Bayer Agrochem K.K. Dichloropyridyl- and dichloroisothiazolyl-thiocarboxamides and their use as microbicides
GB0218827D0 (en) * 2002-08-13 2002-09-18 Syngenix Ltd Anaesthetic compounds and conjugates thereof
EP1679296A4 (en) * 2003-10-14 2007-12-26 Ajinomoto Kk DERIVE ETHERE
EP1679304A4 (en) * 2003-10-24 2006-11-15 Kissei Pharmaceutical AMINO ALCOHOL DERIVATIVE, MEDICAL COMPOSITION CONTAINING THEREOF AND ITS USE
SE0402636D0 (sv) * 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
KR20070068432A (ko) * 2004-10-29 2007-06-29 아스트라제네카 아베 염증 질환의 치료를 위한 글루코코르티코이드 수용체조절제로서의 신규 술폰아미드 유도체
EP1868605A2 (en) * 2005-03-31 2007-12-26 Janssen Pharmaceutica, N.V. Phenyl and pyridyl lta4h modulators
US8012901B1 (en) * 2006-08-30 2011-09-06 Margarita Ortiz-Marciales Method of synthesizing enantiopure mexiletine analogues and novel β-thiophenoxy and pyridyl ethers
EP2154131A4 (en) * 2007-04-26 2011-09-21 Pharmafrontier Co Ltd INHIBITOR OF THE G-PROTEIN-COUPLED RECEPTOR AND PHARMACEUTICAL PRODUCT
RU2010106393A (ru) * 2007-07-26 2011-09-10 Зингента Партисипейшнс Аг (Ch) Новые микробиоциды
PL212489B1 (pl) * 2008-01-22 2012-10-31 Univ Jagiellonski Pochodne fenoksyalkiloaminoalkanoli i ich zastosowania
WO2012050884A2 (en) * 2010-09-28 2012-04-19 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
MX359032B (es) * 2011-09-01 2018-09-12 Hoffmann La Roche Inhibidores de pirrolopirazina cinasa.
WO2013151923A1 (en) * 2012-04-03 2013-10-10 Bristol-Myers Squibb Company Pyrimidinone carboxamides as inhibitors of endothelial lipase

Also Published As

Publication number Publication date
MX370251B (es) 2019-12-06
WO2015017906A1 (pt) 2015-02-12
CN105517991B (zh) 2019-06-07
EP3031794B1 (en) 2019-01-02
CA2920315C (en) 2021-06-15
EP3031794A1 (en) 2016-06-15
JP6602297B2 (ja) 2019-11-06
MX2016001747A (es) 2016-08-18
ES2717125T3 (es) 2019-06-19
JP2016527280A (ja) 2016-09-08
CN108912005A (zh) 2018-11-30
EP3031794A4 (en) 2017-05-03
CN105517991A (zh) 2016-04-20
BR102013020313A2 (pt) 2015-10-06
CA2920315A1 (en) 2015-02-12
US20160214926A1 (en) 2016-07-28
CN108912005B (zh) 2022-01-14
BR102013020313B1 (pt) 2021-07-06

Similar Documents

Publication Publication Date Title
CL2019002103A1 (es) Derivados de tirosinamida como inhibidores de rho-quinasa.
CY1125279T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
SV2016005206A (es) Derivados novedosos de amino pirimidina
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
UY36943A (es) PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y MÉTODO PARA SU USO
BR112015024671A2 (pt) derivados de ureia úteis como inibidores de quinase
CY1120974T1 (el) Ετεροκυκλικες ενωσεις, φαρμακα που περιεχουν τις αναφερομενες ενωσεις, χρηση αυτων και διαδικασιες για την παραγωγη τους
DOP2016000175A (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
SV2010003581A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
BR112015009942A2 (pt) derivados de tiofeno fundidos tricíclicos como inibidores de jak
CL2014000122A1 (es) Compuestos derivados de indazol, inhibidores de janus quinasa (jak); composicion farmaceutica que los comprende; y su uso para tratar rinitis alergica, congestion nasal, asma, bronquitis cronica, artritis, insuficiencia cardiaca, colitis ulcerativa, infeccion viral y bacteriana, cancer y alzheimer, entre otras enfermedades.
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112014031234A2 (pt) derivados de piridinona e piridazinona
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
CL2008001593A1 (es) Compuestos derivados de heterociclos, antagonistas para el ccr2; y uso de los compuestos para tratar afecciones o enfermedades del tracto respiratorio, como enfermedad pulmonar obstructiva cronica y asma.
BR112014014452A2 (pt) derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos
BR112015010467A2 (pt) compostos tiazol benzenossulfonamida
CU20140037A7 (es) Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112015026238A8 (pt) composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
BR112013019416A2 (pt) dimaleato de 9-[4-(3-cloro-2-flúor-fenilamino)-7-metóxi-quinazolin-6ilóxi]-1,4-diaza-espiro[5.5]undecan-5-ona, seu uso como medicamento e sua produção
BRPI1009781A2 (pt) compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B03H Publication of an application: rectification [chapter 3.8 patent gazette]

Free format text: REFERENTE A RPI 2335 DE 06/10/2015, QUANTO AO ITEM (71).

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/08/2013, OBSERVADAS AS CONDICOES LEGAIS.